Spectranetics CVX-300 Panel Review Hindered By Historical Control Arm
This article was originally published in The Gray Sheet
Executive Summary
FDA should have discouraged Spectranetics from conducting a non-randomized trial for critical limb ischemia (CLI), Circulatory System Devices Panel members asserted Oct. 2